Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged 8 Months — United States, April 2024
by from Morbidity and Mortality Weekly Report (MMWR) on (#6R1EK)
This report describes the percentage of infants protected against respiratory syncytial virus from maternal RSV vaccination, nirsevimab, or both.